

# Roman M Chabanon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/199396/publications.pdf>

Version: 2024-02-01

11  
papers

783  
citations

1163117

8  
h-index

1199594

12  
g-index

12  
all docs

12  
docs citations

12  
times ranked

1418  
citing authors

#	ARTICLE	IF	CITATIONS
1	PARP inhibition enhances tumor cellâ€™intrinsic immunity in ERCC1-deficient nonâ€™small cell lung cancer. <i>Journal of Clinical Investigation</i> , 2019, 129, 1211-1228.	8.2	222
2	Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. <i>Clinical Cancer Research</i> , 2016, 22, 4309-4321.	7.0	182
3	Targeting the DNA damage response in immuno-oncology: developments and opportunities. <i>Nature Reviews Cancer</i> , 2021, 21, 701-717.	28.4	150
4	Enduring epigenetic landmarks define the cancer microenvironment. <i>Genome Research</i> , 2018, 28, 625-638.	5.5	74
5	PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer. <i>Cancer Research</i> , 2021, 81, 2888-2902.	0.9	66
6	Exploiting epigenetic vulnerabilities in solid tumors: Novel therapeutic opportunities in the treatment of SWI/SNF-defective cancers. <i>Seminars in Cancer Biology</i> , 2020, 61, 180-198.	9.6	28
7	DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade. <i>Journal of Clinical Investigation</i> , 2018, 128, 1671-1687.	8.2	19
8	Beyond DNA repair: the novel immunological potential of PARP inhibitors. <i>Molecular and Cellular Oncology</i> , 2019, 6, 1-4.	0.7	18
9	BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	11
10	Understanding genetic determinants of resistance to immune checkpoint blockers. <i>Seminars in Cancer Biology</i> , 2020, 65, 123-139.	9.6	9
11	A Novel Synthetic Lethal Approach to Target <i>MYC</i> -Driven Cancers. <i>Cancer Research</i> , 2022, 82, 969-971.	0.9	3